| Similar Articles |
|---|
 |
The Motley Fool
April 18, 2006
Brian Gorman |
PPD Develops Solid Growth The contract research firm cashes in on its core business. Investors celebrated Pharmaceutical Product Development's latest earnings release today by sending the stock up more than 9% in recent trading.   |
The Motley Fool
April 20, 2004
Brian Gorman |
PPD's New Possibilities The royalty stream from dapoxetine could significantly boost earnings. |
The Motley Fool
October 17, 2006
Brian Gorman |
PPD Disappoints? Not Quite Its discovery sciences business hindered results, but PPD remains a winner for investors. |
The Motley Fool
July 15, 2004
Brian Gorman |
Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%. |
The Motley Fool
April 28, 2005
Brian Gorman |
PPD Branches Out The company, which concentrates on running clinical trials for pharmaceutical and biotech clients is right in diversifying, but its strategy carries its own risk. |
AskMen.com
Ian Kerner |
Premature Ejaculation: In Numbers PE is the most common sexual issue a guy can have. It doesn't matter how old you are, how much experience you have or how much you know about sex, it can happen to anyone. Drugs are available that can help. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
